Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07293247 | A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment | recruiting | Phase 2 | 164 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07543172 | CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer | not yet recruiting | Phase 2 | 29 | Roswell Park Cancer InstituteOTHER | 1 | Sep 2, 2026 |
| clinicaltrials |
| NCT07622186 | A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC) | recruiting | Phase 2 | 150 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT03600701 | Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07355231 | Lung Functional Avoidance Radiotherapy Using Hyperpolarized Xenon MRI(GuidedRT) | not yet recruiting | Phase 1 / Phase 2 | 10 | Xemed LLCINDUSTRY | 0 | Sep 1, 2026 | clinicaltrials |
| NCT07486817 | Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab | recruiting | Phase 2 | 60 | Boehringer IngelheimINDUSTRY | 7 | Sep 1, 2026 | clinicaltrials |
| NCT07796438 | Low-Frequency rTMS for In-Hospital Sleep Disturbance in Advanced NSCLC | not yet recruiting | Phase 2 | 160 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 0 | Sep 1, 2026 | clinicaltrials |
| NCT02133196 | T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer | recruiting | Phase 2 | 85 | National Cancer Institute (NCI)NIH | 1 | Aug 31, 2026 | clinicaltrials |
| NCT04736173 | Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer(ARC-10) | active not recruiting | Phase 2 | 169 | Arcus Biosciences, Inc.INDUSTRY | 10 | Aug 31, 2026 | clinicaltrials |
| NCT05013450 | Dupilumab_Metastatic NSCLC | active not recruiting | Phase 1 / Phase 2 | 33 | Thomas MarronOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT05460273 | A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02) | active not recruiting | Phase 1 / Phase 2 | 119 | AstraZenecaINDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT05830058 | Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma | recruiting | Phase 2 | 32 | City of Hope Medical CenterOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07070440 | DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7) | recruiting | Phase 1 / Phase 2 | 180 | Dizal PharmaceuticalsINDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07079475 | Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8) | recruiting | Phase 1 / Phase 2 | 220 | Dizal PharmaceuticalsINDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07322341 | SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer | recruiting | Phase 2 | 32 | University of WashingtonOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT05299125 | Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations(AMIGO-1) | completed | Phase 2 | 54 | Latin American Cooperative Oncology GroupOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT05949606 | A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 95 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07639242 | Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic NSCLC | suspended | Phase 2 | 60 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07789444 | Sacituzumab Tirumotecan（Sac-TMT） and Brain Radotherapy for EGFR+ NSCLC With Brain Mets | not yet recruiting | Phase 2 | 53 | Xiaorong DongOTHER | 0 | Aug 27, 2026 | clinicaltrials |
| NCT00334815 | Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery | active not recruiting | Phase 2 | 29 | National Cancer Institute (NCI)NIH | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06822543 | A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)(TROPICAL-1) | recruiting | Phase 2 | 46 | Latin American Cooperative Oncology GroupOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07158489 | Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC(ORIGIN2) | recruiting | Phase 2 | 47 | Swiss Cancer InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07288177 | Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer(RAINFOL-05) | recruiting | Phase 2 | 240 | GenmabINDUSTRY | 13 | Aug 26, 2026 | clinicaltrials |
| NCT07551778 | Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 42 | BOE Technology Group Co., Ltd.INDUSTRY | 0 | Aug 26, 2026 | clinicaltrials |
| NCT07718672 | Hotspot Stereotactic Ablative Radiotherapy Versus Traditional Stereotactic Ablative Radiotherapy for the Treatment of Early-Stage Non-Small Cell Lung Cancer | recruiting | Phase 2 | 200 | Roswell Park Cancer InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07739186 | A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06) | not yet recruiting | Phase 2 / Phase 3 | 120 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)(STARTRK-2) | active not recruiting | Phase 2 | 534 | Hoffmann-La RocheINDUSTRY | 16 | Aug 25, 2026 | clinicaltrials |
| NCT04165070 | KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) | recruiting | Phase 1 / Phase 2 | 450 | Merck Sharp & Dohme LLCINDUSTRY | 9 | Aug 25, 2026 | clinicaltrials |
| NCT05948813 | TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases | recruiting | Phase 2 | 420 | TYK Medicines, IncINDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06780085 | A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01) | recruiting | Phase 2 | 96 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Aug 25, 2026 | clinicaltrials |
| NCT07250477 | Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer | recruiting | Phase 2 | 56 | University of California, DavisOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07412262 | A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) Expression(NSCLC， YAP) | recruiting | Phase 2 | 32 | Guangdong Association of Clinical TrialsOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07780578 | The Study Of Andamertinib Plus Anlotinib In Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 34 | Fudan UniversityOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT02434081 | NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma(NICOLAS) | completed | Phase 2 | 94 | ETOP IBCSG Partners FoundationNETWORK | 5 | Aug 24, 2026 | clinicaltrials |
| NCT04310020 | Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients | active not recruiting | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05987826 | Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC | recruiting | Phase 2 | 40 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT06385262 | TOP 2301: Neoadjuvant Chemo for NSCLC | suspended | Phase 2 | 63 | Duke UniversityOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT06465329 | A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC) | active not recruiting | Phase 2 | 120 | Regeneron PharmaceuticalsINDUSTRY | 6 | Aug 24, 2026 | clinicaltrials |
| NCT03940703 | A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) | completed | Phase 2 | 140 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 17 | Aug 21, 2026 | clinicaltrials |
| NCT04579380 | Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations | active not recruiting | Phase 2 | 217 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 8 | Aug 21, 2026 | clinicaltrials |
| NCT04699123 | The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 159 | Yale UniversityOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT05797168 | Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors(FONTANA) | recruiting | Phase 1 / Phase 2 | 602 | AstraZenecaINDUSTRY | 12 | Aug 21, 2026 | clinicaltrials |
| NCT04557449 | Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors(CDK4i) | active not recruiting | Phase 2 | 362 | PfizerINDUSTRY | 8 | Aug 20, 2026 | clinicaltrials |
| NCT04902872 | Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 69 | Cybrexa TherapeuticsINDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04933903 | BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab | recruiting | Phase 2 | 25 | Brown UniversityOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05269381 | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors(PNeoVCA) | recruiting | Phase 1 / Phase 2 | 138 | Mayo ClinicOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07133425 | A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer | recruiting | Phase 2 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07329322 | Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer | recruiting | Phase 2 | 30 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07770100 | Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV) | not yet recruiting | Phase 2 | 35 | Mark BernardOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07775040 | Spatially Fractionated Radiotherapy With Tislelizumab and Chemotherapy for Bulky Stage III NSCLC: A Phase II Trial | not yet recruiting | Phase 2 | 43 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Aug 20, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Sep 2, 2026source: clinicaltrials